Tumor expression quantitative trait methylation (eQTM) CpGs and genes are new and efficient candidate targets to be investigated for both prognostic and immune status monitoring purposes. Three cis-eQTM CpGs (cg07786657, cg12446199, and cg00027570) were found to be strongly associated with the tumor immune cytolytic activity score, and one eQTM in TCF7 (cg25947408) was found to be a novel candidate biomarker for uncoupling overall T-cell differentiation and exhaustion status in a tumor. The image depicts the distinct methylation profiles from these CpG sites seen in melanoma tumor samples from four patient subgroups. For details, see the article by Yu and colleagues on page 1724.